TOURS, France and NORCROSS, Ga., Jan. 2—MediPurpose™ has been awarded its first tender by the Centre Hospitalier Régional Universitaire de Tours (CHRU), also known as Tours University Hospitals.
MediPurpose will supply its SurgiLance® Safety Lancets to nine CHRU hospitals over a two-year period, beginning in January 2008 and continuing through December 2009.
MediPurpose was selected over other providers based on CHRU criteria that demanded:
"The trials were a success with the doctors and nurses," said MediPurpose sales and marketing manager Stella Avarre. "We are now honored to serve CHRU and look forward to a lasting relationship."
Founded in 1999, MediPurpose is a leading medical device company headquartered in Singapore, with offices in the United States and the United Kingdom.
Known for its innovation of the SurgiLance® Safety Lancet, MediPurpose has leveraged its success in the medical device industry to become a master medical product distributor.
MediPurpose also offers angel funding, medical product development and medical device consulting for medical device inventors and medical product companies seeking entrance or expansion into the medical device markets.
For more information about MediPurpose's medical products, medical distribution channel management services and medical product development services, please visit www.medipurpose.com.
France Office Contact
1 Bis Rue de Verdun
Domaines des Erables
78110 Le Vesinet
FRANCE
Tel: +33 (0) 1 39 76 95 22
Fax: +33 (0) 1 39 76 01 26
© 2012 MediPurpose Private Limited | About Us | Contact Us | Terms of Use
Join MediPurpose on 
